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Improvement of Right Ventricular Hemodynamics
with Left Ventricular Endocardial Pacing during Cardiac
Resynchronization Therapy
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STEVEN A. NIEDERER, PH.D.,* and CHRISTOPHER A. RINALDI, M.D.*,†
From the *Division of Imaging Sciences and Biomedical Engineering, King’s College London, London, UK;
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Background: Cardiac resynchronization therapy (CRT) with biventricular epicardial (BV-CS) or
endocardial left ventricular (LV) stimulation (BV-EN) improves LV hemodynamics. The effect of CRT
on right ventricular function is less clear, particularly for BV-EN. Our objective was to compare the
simultaneous acute hemodynamic response (AHR) of the right and left ventricles (RV and LV) with BV-CS
and BV-EN in order to determine the optimal mode of CRT delivery.
Methods: Nine patients with previously implanted CRT devices successfully underwent a temporary
pacing study. Pressure wires measured the simultaneous AHR in both ventricles during different pacing
protocols. Conventional epicardial CRT was delivered in LV-only (LV-CS) and BV-CS configurations and
compared with BV-EN pacing in multiple locations using a roving decapolar catheter.
Results: Best BV-EN (optimal AHR of all LV endocardial pacing sites) produced a significantly greater
RV AHR compared with LV-CS and BV-CS pacing (P < 0.05). RV AHR had a significantly increased
standard deviation compared to LV AHR (P < 0.05) with a weak correlation between RV and LV AHR
(Spearman rs = −0.06). Compromised biventricular optimization, whereby RV AHR was increased at the
expense of a smaller decrease in LV AHR, was achieved in 56% of cases, all with BV-EN pacing.
Conclusions: BV-EN pacing produces significant increases in both LV and RV AHR, above that
achievable with conventional epicardial pacing. RV AHR cannot be used as a surrogate for optimizing
LV AHR; however, compromised biventricular optimization is possible. The beneficial effect of
endocardial LV pacing on RV function may have important clinical benefits beyond conventional CRT.
(PACE 2016; 00:1–11)
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Introduction
Cardiac resynchronization therapy (CRT) is an
effective treatment for symptomatic heart failure
(HF) patients with significantly impaired left
ventricular (LV) function and prolonged QRS
duration; however, 30–40% of patients fail to
derive clinical benefit.1 Attempts to improve
CRT response have focused on improving both
preprocedural2–5 and intraprocedural6–8 predic-
tors of response, as well as alternate forms of CRT
delivery.9–12
LV acute hemodynamic response (AHR) is
a frequently used tool for CRT clinical research
studies. Improvements in LV and/or right ven-
tricular (RV) hemodynamics with CRT have been
demonstrated13–16; however, the latter are often
neglected with respect to CRT optimization.
doi: 10.1111/pace.12854
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Furthermore, the RV AHR has been shown to
positively correlate with cardiac index, which
supports the hypothesis that improvement of this
acute metric may have an important and positive
contribution on cardiac output.14 It is biologically
plausible that biventricular (BV) optimization
with simultaneous attention to the hemodynamic
changes in both ventricles may be clinically
beneficial. Biventricular endocardial pacing (BV-
EN) has been shown to improve LVAHR compared
to epicardial pacing11,12,17,18; however, the effect of
BV-EN on RV AHR is less clear. A recent canine
study demonstrated that the RVmyocardiumplays
a key role in work redistribution and improved
LV pump function with CRT but RV AHR was not
significantly improved by LV-only or BV epicar-
dial pacing,19 despite simultaneous increases in
LV AHR. However, the effect of BV-EN pacing on
RV AHR was not addressed in that study.
The aim of the current studywas to investigate
the effect of epicardial and endocardial CRT on
simultaneous RV and LV AHR. We hypothesized
that: (1) BV-EN has a greater capacity to improve
RV AHR more than conventional epicardial
pacing; and (2) RV AHR could also be optimized
concurrently to LV AHR, resulting in improved
overall cardiac function. To test these hypotheses,
and to investigate if RV AHR could be used as a
surrogate for LV AHR, we performed a comparison
of BV AHR to various pacing protocols including
epicardial pacing via the coronary sinus in LV-
only (LV-CS) and biventricular modes (BV-CS) as
well as BV-EN.
Methods
This study complies with the Declaration
of Helsinki, the protocol was approved by the
local ethics committee, and informed consent
was obtained from each patient. Ten patients
with conventional CRT criteria (New York Heart
Association [NYHA] Class II–IV drug refractory
HF, LV ejection fraction 35%, and QRS 
120 ms) with previously implanted CRT systems,
were recruited for an acute electrophysiol-
ogy/pacing study. Patients were intentionally
selected with a phenotype of suboptimal response
to CRT as they have the most to gain by alternate
strategies: Male patients with ischemic etiology
and QRS duration 120–150 ms.20 Patients with a
mechanical aortic valve or significant peripheral
vascular disease were excluded.
Baseline assessment prior to original
implant included clinical assessment (NYHA
functional class), 12-lead electrocardiogram, and
2D echocardiography (echo). Etiology of HF was
confirmed on the basis of clinical history, coronary
angiography, and cardiac magnetic resonance
(CMR) imaging. An improvement of ventricular
AHR by >10% defined an acute hemodynamic
responder.6
Invasive Hemodynamic Study
Patients underwent an invasive study at
least 3 months following implantation of the
CRT device. Light sedation was used and a
steerable 6F Livewire decapolar catheter (St. Jude
Medical St. Paul, MN, USA) was passed via the
femoral artery retrogradely to perform endocardial
pacing from multiple sites within the LV cavity.
Intravenous heparin (70U/kg)was administered to
achieve systemic anticoagulation (target-activated
clotting time 300–350 seconds). A 0.014-inch
diameter high-fidelity Certus PressureWire (St.
Jude Medical) was placed retrogradely into the LV
cavity via the femoral or radial artery to assess real-
time mean LV dPdtmax using the accompanying
PhysioMon software (RADI Medical Systems, part
of St. Jude Medical). An RV pressure wire was
inserted via cannulation of the femoral vein and
catheterization of the right heart to measure simul-
taneous RV dPdtmax. Atrial pacing (or RV pacing
for atrial fibrillation) at 5–10 beats/min above the
intrinsic rate was used as the baseline and was a
constant for each patient throughout different pac-
ing modes. At least 20 seconds was respected after
any change in pacing protocol, in order to achieve
hemodynamic stabilization prior to recording
pressure measurements for 20 seconds. The mean
dPdtmax for each pacing protocol was determined
by averaging the dPdtmax over the recorded
period following removal of beats affected by
ventricular extra systoles (Fig. S1). The AHR
was defined to be the percentage change in the
maximal increase in the rate of change of pressure
(denoted dPdtmax) with the intervention protocol
as compared with its associated baseline protocol.
To minimize the known effect of baseline drift in
dPdtmax throughout the case, the baseline was re-
assessed prior to every change in pacing modality.
The sensed and paced atrioventricular (AV)
and ventriculo-ventricular (VV) settings of the
device were optimized using echocardiography,
6 weeks after the original implantation; the
mean of these values is shown in Table I.
For the acute pacing study, a set AV delay of
100 ms was used for all patients. No AV or VV
optimization was performed during this study due
to the added time these require, and our intention
to focus on endocardial pacing from multiple
locations (VV pacing was simultaneous in all pa-
tients).Mean and standard deviation (SD) pressure
metrics were also recorded for each heartbeat in-
cluding the averaged peak systolic pressure (max-
imum pressure per beat), start diastolic pressure
(minimum pressure per beat), and end diastolic
2 2016 PACE, Vol. 00
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Table I.
Baseline Demographics, Device Settings, and CRT
Response
Demographics
Pre-CRT implantation
Mean age (years) 70 ± 7
Male 9 (100%)
Sinus rhythm 6 (67%)
Ischemic heart disease 7 (78%)
QRS duration (ms) 152 ± 37
LBBB morphology 9 (100%)
NYHA class III 7 (78%)
LV systolic function, EF by echo (%) 30 ± 8
RV systolic function: TAPSE (mm) 13 ± 4
RV basal diameter, diastole (mm) 41 ± 8
RV systolic function, EF by MRI (%) 43 ± 10
CRT settings
Sensed AV delay (ms) 120 ± 22
Paced AV delay (ms) 135 ± 15
VV timing: LV ahead (ms) 17 ± 13
CRT response assessment at 6 months
LV systolic function, EF by echo (%) 32 ± 11
RV systolic function: TAPSE (mm) 14 ± 2
RV basal diameter, diastole (mm) 39 ± 10
Echo responder 3 (33%)
Clinical responder 5 (56%)
Averaged data are mean ± SD.
AV = atrio-ventricular; CRT = cardiac resynchronization therapy;
ECHO = echocardiography; EF = ejection fraction; LBBB =
left bundle branch block; LV = left ventricular; MRI = magnetic
resonance imaging; NYHA = New York Heart Association;
RV = right ventricular; TAPSE = Tricuspid Annular Plane Systolic
Excursion; VV = ventricular-ventricular.
pressure, which was defined to occur when the
rate of increase of pressure traversed 100mmHg/s.
Pacing Protocols
Baseline dPdtmax was compared with paced
dPdtmax for the following pacing protocols:
1. LV-only epicardial CRT using the im-
planted LV lead (LV-CS);
2. BV epicardial CRT using the RV lead and
the implanted LV lead (BV-CS);
3. BV endocardial pacing using the RV lead
and the roving LV decapolar catheter (BV-EN) in
multiple positions at random.
BV AHR Optimization
BV AHR optimization involved a review
of paired LV and RV AHR data in order to
delineate the optimal protocols for both ventricles
simultaneously. As conventional CRT optimiza-
tion by AHR maximizes LV AHR only, BV AHR
optimization (incorporating both LV and RV
AHR metrics) will almost certainly involve some
decrease in LV AHR. We therefore adhered to
the following principle when selecting BV AHR
optimization: the increase in RV AHR must be
greater than the decrease in LV AHR, compared
with the maximal LV AHR protocol (Fig. S2), as
the effect of RV dPdtmax on RV function and
subsequent clinical outcome is less clear than that
of the LV.
To construct a BV optimization metric, which
must be relative to the response achieved by
the maximal LV AHR protocol, we denote the
response achieved by conventional AHR and
BV AHR optimization with subscripts LV and
BV, respectively, and the comparative change in
ventricular AHR from that of the maximal LV AHR
protocol by LV = (LV AHR)BV − (LV AHR)LV
and RV = (RV AHR)BV − (RV AHR)LV. Then it is
proposed to use the ratio of the change in RV AHR
(RV) to the absolute change in LV AHR (|LV|),
giving the ratio RV/|LV|, as a quantitative
measure of BV AHR performance relative to the
conventional optimization method. This metric is
applied to all protocols that did not maximize
LV AHR and a protocol is deemed to be a viable
alternative to the conventionally chosen protocol
when the metric value is >1. The viable protocol
that maximizes this BV AHR optimization metric
is the chosen alternative BVoptimization protocol.
Conceptually, if one considers the set of points
given by the relative response of a protocol
compared to the maximal LV AHR protocol in
the LV AHR, RV AHR Cartesian plane, then
this process selects the protocol with the largest
negative slope of the line joining the compromise
protocol datum to the origin (Fig. S2).
Statistical Methods
Statistical quantities were computed using
MATLAB (R2013b, The MathWorks, Cambridge,
MA, USA). Values were presented as numbers
and percentages for discrete variables and as
mean ± SD for continuous variables. Bivariate
correlations were quantified using both Pear-
son’s parametric correlation coefficient (rp) and
Spearman’s nonparametric rank-order correla-
tion coefficient (rs). One-way balanced repeated
measures analysis of variance (ANOVA) was
used to test for significant effects of the three
pacing methods (LV-CS/BV-CS/best BV-EN) on
baseline hemodynamics, where “best BV-EN”
denotes maximal endocardially paced AHR for
each patient averaged over all patients, as opposed
PACE, Vol. 00 2016 3
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Figure 1. Scatterplot of paced LV and RV pressure data acquired from nine patients undergoing various pacing
protocols (LV only-coronary sinus = LV-CS; biventricular-coronary sinus = BV-CS; biventricular endocardial
pacing = BV-EN). (A) Peak systolic (PSP), start diastolic (SDP), and end diastolic (EDP) pressures. Simple linear
regression was applied to each pressure metric (m-slope; c-intercept). (B) Detailed analysis of EDP by pacing type. LV
= left ventricular; RV = right ventricular.
to “average BV-EN,” which denotes the mean
endocardially paced AHR-AHR for each patient
averaged over all patients. Pairwise analysis for
differences between epicardial pacing strategies
(LV-CS/BV-CS) and endocardial pacing (best
BV-EN/average BV-EN) was performed using a
two-tailed Student’s t-test. A P-value <0.05 was
considered statistically significant for all analyses.
Results
Patient Demographics (Table I)
Nine datasets were included in the analysis
due to the recurrent dislodgement of the RV pres-
sure wire during one procedure. The distribution
of CRT devices was as follows: St. Jude Medical
Quadra Assura (n = 3); Promote Quadra (n =
5); and Medtronic Consulta (n = 1). The mean
age was 70 ± 7 years, mean QRS duration was
152 ± 37 ms, and all patients had left bundle
branch block (LBBB). The majority of participants
had cardiomyopathy secondary to ischemic heart
disease (78%) and were in sinus rhythm (67%).
Patients had impairment of both LV and RV
systolic function prior to device implantation.
Mean LV ejection fraction was 30 ± 8%,
mean Tricuspid Annular Plane Systolic Excursion
(TAPSE) was 13 ± 4 mm (normal > 16 mm21),
mean RV basal diameter was 41 ± 8 (normal
< 42 mm21), and mean RV systolic function mea-
sured with CMR was 43 ± 10% (normal range 40–
68%). The mean time from CRT implantation to
study participation was 15 ± 15 months. Patients
were assessed for CRT response at 6 months
following implantation. Response was determined
using the Packer clinical composite score22 and
with 2D echo, whereby an echo responder was
defined as a patient with 15% reduction in end
systolic volume. This cohort of patients had a high
proportion of CRT nonresponse, six of nine (67%)
as measured by echo and four (45%) as measured
by clinical composite score. Endocardial pacing
was performed in several positions from base to
apex in each patient in a random fashion. The
mean number of endocardially paced positions per
patient was 8.4 ± 3.7 (Table S1).
Correlation of Interventricular Pressure and
AHR Metrics
Biventricular and patient-specific measure-
ments of peak systolic pressure, start diastolic
pressure, and end diastolic pressure are presented
in Table S2 in the Supporting Information.
RV and LV start and end diastolic pressure
measurements displayed a positive correlation
(start: rp = 0.77, rs = 0.84; end: rp = 0.79, rs =
0.82). Simple linear regression analysis of the start
and end diastolic pressure relationships yielded
coefficients of determination of r2 = 0.59 and
r2 = 0.63, respectively (Fig. 1). Compared to the
diastolic pressure measurements, peak systolic
pressures had a reduced positive correlation
(rp = 0.11, rs = 0.12 [Table S2]) and a reduced
linear model coefficient of determination of r2 =
4 2016 PACE, Vol. 00
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Table II.
Correlation between RV and LV AHR
LV AHR(%) RV AHR(%) Correlations
ID Maximum Average Maximum Average rP rS
1 3.9 −1.0 ± 3.7 15.3 4.2 ± 7.2 0.56 0.54
2 61 19.5 ± 18.9 24.1 1.3 ± 14.4 0.79 0.72
3 34.2 10.3 ± 9.6 51.7 9.7 ± 23.6 −0.04 −0.14
4 14.3 5.1 ± 4.3 57.5 24.3 ± 24.9 0.08 0.05
5 13.8 6.2 ± 3.9 65.1 32.8 ± 24.0 −0.19 0.19
6 25.6 17.6 ± 7.5 6 −10.9 ± 10.9 −0.41 −0.25
7 7.6 0.3 ± 5.7 18.9 6.8 ± 9.1 0.40 0.37
8 21.4 0.2 ± 8.9 101 25.0 ± 35.5 0.77 0.76
9 25 12.4 ± 11.1 9.9 4.1 ± 5.7 0.91 1.00
All 61 7.6 ± 11.7 101 10.6 ± 24.4 0.00 −0.06
Comparison of interventricular sensitivity of AHR across all pacing protocols (BV-CS, LV-CS, and BV-EN). Individual and whole-cohort
maximum and averaged AHR (mean ± SD) were calculated for both ventricles.
AHR = acute hemodynamic response; ID = anonymized patient number; rP = Pearson’s correlation coefficient; rS = Spearman’s rank
correlation coefficient. SD = standard deviation. Other abbreviations as in previous tables.
Figure 2. Scatterplot of all paired LV-RV AHR data
for nine patients, split by conventional coronary sinus
pacing (a single protocol of LV-CS/BV-CS for each
patient) and BV endocardial pacing (BV-EN) protocols
at multiple locations per patient. An AHR value >10%
above baseline was used as the benchmark for a
positive AHR, as indicated by the dashed lines.6 Using
this cutoff, data points are thus divided into LV-
only response, RV-only response, BV response, and
nonresponse. AHR = acute hemodynamic response.
Other abbreviations as in Figure 1.
0.013 (Fig. 1A). Overall, LV and RV AHR were
poorly correlated as can be qualitatively seen by
the nonlinear distribution of data in Figure 2, and
is quantitatively demonstrated by the correlation
coefficient cohort averages of rp = 0.005 and rs =
−0.055 (Table II). The lack of a linear relationship
between LV and RV AHR was also displayed
on an individual basis (Fig. S3) as demonstrated
by the wide range of patient-specific correlation
values of Table II.
Comparison of Epicardial versus Endocardial
CRT on BV AHR (Table III and Figs. 3 and 4)
LV AHR was improved by 8.4 ± 8.7%
from baseline by BV-CS (P = 0.02) and
6.6 ± 8.6% by LV-CS (P = 0.051) (Table III).
Notably, RV AHR was not improved by either BV-
CS (2 ± 15.9%, P = 0.712) or LV-CS (0.9 ± 12.3%,
P = 0.832). The best BV-EN, however, produced
significantly improved AHR for both ventricles
compared with conventional epicardial pacing
(Fig. 3). The average LV and RV increase in AHR
with BV-EN was 21.4 ± 16.6% and 37.1 ± 31.8%,
respectively (Fig. 3). In a pairwise comparison
of pacing methods, best BV-EN was a significant
improvement in terms of RV AHR over BV-CS
(P = 0.021) and LV-CS (P = 0.02). Best BV-EN
was also a significant improvement in terms of
LV AHR over LV-CS (P = 0.04) but not BV-CS
(P = 0.065).
The average SD of RV AHR across all patients
was greater than that of the LV (±18% vs ±8%).
The SD for the RV AHR under all three pacing
methods was larger than the SD of the equivalent
LV AHR (Fig. 3).
A patient-specific comparison of the BV
AHR performance of best epicardial and best
endocardial pacing under conventional LV AHR
PACE,Vol. 00 2016 5
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Table III.
Hemodynamic Data from HF and LBBB Patients (n = 9) during Baseline and CRT Pacing
Variable Baseline LV-CS BV-CS BV-EN ANOVA (P-Value)
LV start diastolic
pressure (mm Hg)
5.2 ± 11.9 5.5 ± 11.9 4.0 ± 10.4 5.3 ± 11.0 0.992
LV end diastolic
pressure (mm Hg)
19.0 ± 15.4 20.1 ± 13.6 14.8 ± 12.7 19.8 ± 11.8 0.822
LV peak systolic
pressure (mm Hg)
103.2 ± 19.8 103.6 ± 19.7 102.2 ± 18.5 107.3 ± 18.2 0.948
LV dPdtmax (mm Hg/s) 808.1 ± 247.2 856.2 ± 252.9 863.1 ± 243.4 989.5 ± 290.4 0.501
LV AHR (%) 0.0 ± 0.0 6.6 ± 8.6 8.4 ± 8.7 21.3 ± 17.6 0.036
RV start diastolic
pressure (mm Hg)
−5.1 ± 6.2 −5.2 ± 6.8 −4.4 ± 5.2 −3.6 ± 5.5 0.933
RV end diastolic
pressure (mm Hg)
1.7 ± 8.4 2.9 ± 9.3 2.0 ± 7.2 3.8 ± 7.9 0.946
RV peak systolic
pressure (mm Hg)
29.4 ± 16.4 28.6 ± 15.5 30.1 ± 15.9 32.4 ± 15.6 0.961
RV dPdtmax (mm Hg/s) 341.4 ± 91.3 348.1 ± 107.5 348.2 ± 96.2 453.1 ± 173.3 0.176
RV AHR (%) 0.0 ± 0.0 0.9 ± 12.3 2.0 ± 15.9 35.0 ± 32.3 0.004
AHR= acute hemodynamic response; ANOVA= analysis of variance; BV-CS= biventricular coronary sinus pacing; BV-EN= biventricular
endocardial pacing; HF = heart failure; LV-CS = left ventricular coronary sinus pacing. Other abbreviations as in previous tables.
Figure 3. Bar chart (mean ± SD) comparing mean
BV AHR resulting from LV coronary sinus (LV-CS,
n = 9), BV coronary sinus (LV-CS, n = 9), and
BV endocardial (BV-EN, n = 76) pacing. Best BV-
EN significantly improved ventricular AHR over LV-
CS for both ventricles and over BV-CS for the right
ventricle. There was no statistical difference between
LV-CS and BV-CS for either ventricle, nor was there
a statistical difference between CS pacing and the
average BV-EN AHR for either ventricle. * denotes
statistically significant. SD = standard deviation. Other
abbreviations as in previous figures.
optimization is presented in Figure 4. For
epicardial pacing (LV-CS/BV-CS) and with
respect to AHR (10% cutoff), there were three
nonresponders, two RV-only responders, four
LV-only responders, and zero BV responders.
The average AHR for epicardial pacing was 9.1%
and −1% for the LV and RV, respectively. For
endocardial pacing (BV-EN) and with respect to
AHR, there was one nonresponder, one RV-only
responder, three LV-only responders, and four
BV responders. The average AHR for best BV-EN
pacing increased relative to epicardial pacing to
21.3% and 22.2% for the LV and RV, respectively.
Overall, best BV-EN as opposed to epicardial
pacing increased the number of LV responders by
22% and the number of RV responders by 33%.
Biventricular Hemodynamic Optimization
(Fig. 5)
BV-EN produced 77% of the patient-
specific best LV AHR pacing protocols. Using
the aforementioned BV AHR optimization metric,
56% patients had an alternative viable protocol
(Table S3). Conventional LV AHR optimiza-
tion resulted in one nonresponder, one RV-
only responder, four LV-only responders, and
three BV responders. In contrast, our alternative
BV AHR optimization method resulted in zero
nonresponders, three RV-only responders, two
LV-only responders, and four BV responders. The
6 2016 PACE, Vol. 00
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Figure 4. Patient-specific paired biventricular AHR
data using LV AHR data alone to find the best
epicardial (LV-CS or BV-CS) pacing protocol and
the best endocardial (BV-EN) protocol per patient
(plotted with its associated RV AHR). The resulting
endocardial-epicardial BV AHR pair for each patient
is connected by the gray solid line. An AHR value
>10% above baseline was used as the benchmark for
a positive AHR, as indicated by the dashed lines.6
Mean of the best epicardial protocols (by LV AHR
alone) showminimal/no change in RV-AHR (0%) with
approximately 10% improvement in LV AHR (X). This
compared with a +21% improvement in LV AHR and
similar improvement in the paired RV AHR with the
mean of best endocardial protocols (+). Seven of nine
patients improved LV AHR with BV-EN compared to CS
pacing. The axes are scaled differently. Abbreviations
as in previous figures.
averaged LV-optimized AHR was 23% and 16%
for the LV and RV, respectively, which can be
compared with the averaged BV-optimized AHR
of 21% and 36% for the LV and RV, respectively.
Thus, BV AHR optimization resulted in a greater
than twofold increase in mean RV AHR at the
relatively minor expense of an approximately 2%
decrease in mean LV AHR compared to LV-only
AHR optimization.
Optimal LV Pacing Site Location (Fig. 6)
The optimal site for the LV lead whilst
delivering BV pacing was highly patient-specific,
scattered across most regions of the myocardium
whether the optimal LV AHR alone or RV AHR
alone was used. Where viable alternative BV
optimization protocols existed, four of five (80%)
had the LV lead position clustered in the basal-
mid- anterolateral position. LV lead positionswere
endocardial in 12 of 18 cases when looking at the
Figure 5. Alternative, patient-specific biventricular
AHR optimization. Here, the best patient protocol
selected using LV AHR are compared to an alternative,
BVAVR optimization protocol and connected by arrows
where a viable alternative exists (five out of nine;
Table A3). BV endocardial protocols were optimal
in seven of nine (eight out of nine) cases under
conventional (BV) optimization. The axes are scaled
differently. Abbreviations as in previous figures.
Figure 6. 17-Segment American Heart Association plot
displaying the approximate location and pacing type
(epicardial or endocardial) of the maximal achieved
AHR for the LV (circle), RV (square), and BV (star; see
Fig. 5). Note that four of nine patients did not have a
viable compromise protocol for BV AHR optimization.
Abbreviations as in previous figures.
optimal AHR (LV AHR alone, n = 9 and RV AHR
alone, n = 9); the remaining six of 18 cases were
in an epicardial position.
Discussion
To our knowledge, this study is the first to
simultaneously analyze the effect of epicardial and
PACE, Vol. 00 2016 7
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endocardial pacing on LV and RVAHR in humans.
The principal findings were:
1. Best BV-EN produced a significant im-
provement in the AHR of both ventricles com-
pared with conventional epicardial pacing;
2. Compromise optimization is possible and
may be helpful in the improvement of overall
biventricular function, i.e., by accepting a small
reduction in LVAHR, a relatively greater improve-
ment in RV AHR can often be achieved;
3. The measurement of RV AHR is more
sensitive to pacing perturbations than LV AHR;
4. A weak correlation exists between the RV
and LV AHR, thus the former cannot be used as a
surrogate for the latter.
CRT is an efficacious therapy for selective
patients with HF, yet this treatment is associated
with a significant nonresponse rate. Reasons for
poor response to CRT are well documented,23
including incomplete resynchronization leading
to persistent dyssynchrony and suboptimal lead
placement. While alternative epicardial pacing
strategies are being considered,24 LV endocardial
stimulation is increasingly being investigated
as it has several advantages over conventional
epicardial pacing: (1) there is no access constraint
to myocardial sites subtended by the CS, which
is important given the significant individual
variation with regard to the optimal LV pacing
site10,18; (2) endocardial pacing produces more
physiological activation of the LV and more
favorable tissue repolarization.25,26 Our findings
are in keeping with previous clinical studies,
which suggest that endocardial pacing produces
a superior LV AHR compared with epicardial pac-
ing, and that LV AHR is highly site-specific.3,18,27
Indeed, patients with a suboptimal response
to conventional CRT have been demonstrated
to show both clinical and echocardiographic
improvement from endocardially delivered LV
stimulation for BV pacing.28
Importantly, our results suggest that the su-
perior acute hemodynamic effects of endocardial
pacing over conventional epicardial CRT may
be extended to the RV as well (Fig. 2). As
expected, the mean of the best achievable LV AHR
increased from conventional epicardial BV pacing
to endocardial BV pacing (Fig. 4). In addition,
this increase was accompanied with a rise in the
corresponding RV AHR inferring that some of
the beneficial effects of biventricular pacing could
bemediated through improvement in RV function.
Comparison with Previous Studies
The similar improvement in LV AHR with
LV-CS or BV-CS configurations (Fig. 3) is in
keeping with the findings of Lumens et al.19
Using computational modeling and experimental
hemodynamic measurements in canines, they
showed a nonsignificant difference in LV AHR
improvement between LV-CS and BV-CS pacing,
and a nonsignificant improvement in RV AHR
from either epicardial pacing mode.19 The addi-
tional application of BV-EN pacing in this study
produced a substantial increase in maximal RV
AHR, which may be linked to an enhanced ability
to redistribute myocardial fiber work by altering
the endocardial pacing location.19
The greater increase in RV AHR from BV-
EN as opposed to epicardial pacing is contrary
to the findings of the acute LBBB canine model
study of van Deursen et al.25 where only BV
epicardial pacing led to a statistically signifi-
cant increase in RV AHR. Several key factors
may explain these seemingly opposing findings:
(1) interspecies differences (canine vs human);
(2) pericardial pressure differences—the canine
experiment was performed in open-chest dogs
with the pericardium removed, whereas this study
was conducted in vivo via cardiac catheterization;
and (3) disease state—the canines were acute
radiofrequency-ablated LBBBmodels, whereas the
study participants were chronic HF patients with
long-term implanted CRT devices (Table I).
We have shown for the first time that
compromise BV optimization can be performed
and may be useful in selected patients. Out of
nine patients, five were found to have a viable
BV-optimized pacing response. While 77% (seven
out of nine) of patients achieved maximal LV
AHR from BV-EN, this proportion increased to
88% (eight out of nine) when the alternative BV
hemodynamics optimization was retrospectively
applied (Fig. 5); thus, the ability to increase BV
hemodynamic function appears to be feasible with
endocardial pacing. BV optimization resulted in
an average increase of RV AHR by 20% at the
expense of only a 2% decrease in LV AHR,
compared to conventionally optimized AHRs.
Clinical Relevance
AHR is an accurate reflection of acute pump
function but whether changes in maximum dPdt
translate into better clinical outcomes is yet to
be proven in a large-scale study. Our group is
currently conducting a multicenter, international,
randomized study (RADI CRT – NCT 01464502)
to formally assess this. Whatever the outcome,
an intra-arterial measurement as a predictive
tool nonetheless carries a risk of thromboembolic
stroke. Thus it would be clinically advantageous
to circumvent this risk by using a surrogate, such
as the RV AHR. Our data, however, suggest that a
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weak correlation exists between LV AHR and RV
AHR and does not support the use of RV AHR as
a surrogate for LV function. This weak correlation
may be due to an increased sensitivity of the RV
AHR to pacing perturbations compared to the LV
AHR (Fig. 3).
Endocardial pacing can increase not only
the average LV AHR but also the corresponding
RV AHR over epicardial pacing, and therefore
incorporation of BV optimization to identify the
optimal position for the LV lead may translate into
improved long-term clinical outcomes. However,
if adopting a BV AHR approach, it is unknown
what reduction in LV AHR, if any, is acceptable in
order to improve RV AHR and maintain a positive
clinical outcome. For example, ambiguity exists
with patient no. 3 (Table S3 and Fig. 5) where an
alternative viable protocol results in a reduction
of LV-AHR from 34% to 21% while increasing
RV AHR from 2% to 49%. A larger clinical study
to examine the long-term clinical outcomes of
BV optimization and the relationship between
LV and RV AHR would be needed, and should
include a thorough investigation of the clinical
relevance of more complex BV optimization
metrics than the simple metric adopted in this
study.
Study Limitations
We intentionally selected ischemic patients
for whom response to CRT was suboptimal; this
clearly leads to selection bias, however, this
patient group has the most to gain from alternate
pacing strategies and incorporation of different
AHR protocols (such as using the RV AHR in
combination with the LV AHR rather than the
latter alone).
Although we have studied a small number of
patients, we have a large number of data points
within this group, which we believe provides
sufficient information for analysis and has resulted
in statistically significant findings. Only limited
substrate data were available and therefore we
did not investigate the relationship between acute
response and myocardial fibrosis, which is known
to affect clinical outcomes from CRT.29 The
AHRs reported in these patients are on average
15 months after CRT implantation. It is known
that LV remodeling (whether positive or negative)
often occurs between 3–6 months6; thus, AHR
values at 15 months are unlikely to be the same
as those at implantation and caution needs to
be applied in the extrapolation of these findings
to patient AHR at the time of implant. We also
acknowledge that as a result of the anatomical
restrictions of the coronary veins, we have more
data points with endocardial pacing and therefore
had a greater opportunity to achieve a better
AHR with endocardial pacing.30 However, our
results are similar to published data suggesting
that endocardial pacing involves access to the
fast-conducting His-Purkinje tissue and may be
a preferential location for LV stimulation in
delivering CRT.25,26,31
An important assumption of the current
manuscript is that a higher RV dPdtmax equates
with an improvement in RV function. In support of
this there are published data that the RVAHRposi-
tively correlates with the cardiac index supporting
the hypothesis that improvement in this acutemet-
ricmay have a positive and important contribution
on cardiac output.14 It should be acknowledged,
however, that this may not necessarily be the
case in all HF patients where a decrease in LV
function may lead to an increase in RV afterload
and so higher RV pressure may not necessarily
be a positive sign. Similarly the right side of
the heart acts more as a volume and capacitance
conduit than a high-pressure pump, which exists
on the left side, and therefore, the interpretation
of the concept of RV or BV optimization may
not be straightforward. Our findings of a change
in the relation between RV and LV dPdtmax do,
however, highlight the fact that changes in LV
function are linked to RV function and vice versa.
Conclusions
BV-EN pacing has greater capacity to
improve RV as well as LV AHR compared with
conventional epicardial pacing. A new metric of
compromised biventricular optimization, where
RV AHR is increased for a relatively smaller
decrease in LVAHR, is feasiblewith BV-ENpacing
and may be of clinical benefit in patients with
a poor CRT response to epicardial pacing. The
weak correlation between LV and RV AHR across
all tested pacing modes does not support the use
of RV AHR as a surrogate measure of LV AHR.
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Supporting Information
Additional Supporting Informationmay be found in the online version of this article at the publisher’s
website:
Table S1: Patient-Specific Pacing Group Breakdown of the Total Dataset.
Table S2: Individualized Interventricular Pressure Metrics Correlations.
Table S3: Conventional and Alternative CRT Optimizations of Biventricular Function.
Figure S1: Example processing of an individual pacing protocol using our bespoke software “pTool.”
This software allows for the rapid removal of ectopic beat effects from the analyzed dataset. Ectopic
beats were observed to have an influence on one beat prior- and up to two beats postectopic; thus, data
from these beats were selected for removal from data analysis (shaded beat windows). Quantities of
interest in the remaining beat windows were then analyzed to produce protocol-averaged metrics
(mean ± standard deviation), e.g., peak systolic pressure, start diastolic pressure, end diastolic
pressure, and dPdtmax.
Figure S2: The datum corresponding to the maximal LV AHR protocol is located at the bottom right
hand corner of each panel (i.e., (0,0)); the BVAHR of all other protocols are located relative to this data
point. Viable compromise protocols are those that lie in the white triangular region, i.e., RV −LV,
meaning that the enhanced RV response is greater than the diminished LV response. The vertical blue
line indicates the 80% potential cutoff line as one possible strategy for selecting alternative protocols.
Based on this BV optimized approach, three patients would have viable alternative protocols (patients
1, 5, and 6). AHR = acute hemodynamic response; BV = biventricular; LV = left ventricular; RV =
right ventricular.
Figure S3: Scatterplot of all paired LV-RVAHRdata. The number is anonymized patient identification,
and the green, red, and lilac colors correspond to BV-EN, BV-CS, and LV-CS pacing, respectively.
Acute ventricular response occurs for an AHR value >10% (indicated by the dashed lines).6 Note that
patient 9 is the only patient not to improve via endocardial pacing as opposed to via the coronary
sinus. This patient had the least number of endocardial protocols tested (n = 2) compared to all other
patients (Table S1). AHR = acute hemodynamic response; BV = biventricular; CS = coronary sinus;
EN = endocardial; LV = left ventricular; RV = right ventricular.
PACE, Vol. 00 2016 11
